Come & join us - we're looking for a #clinicalfellow in #UroOncology @mcrcnews.bsky.social @estroradiotherapy.bsky.social @nuradh.bsky.social x.com/i/status/206...

Prof Ananya💙 @achoud72.bsky.social (@achoud72) on X

We're looking for a #clinicalfellow to join the #UroOncology team. 🤙🏽if you're interested! @MCRCnews @ESTRO_RT @RCRadiologists @docpriyamvada @schin_au @syeepei @OncoAlert https://t.co/n9kjPMDxTz

x.com

Delighted to be in beautiful Negrar with the faculty and fantastic hosts @alongi_filippo Gearing up to debate adaptive #radiotherapy - I'm against!😉 @estroradiotherapy.bsky.social @mcrcnews.bsky.social x.com/i/status/206...

Filippo Alongi (@alongi_filippo) on X

The opening dinner of the Adaptive course in Negrar, this year focused on GU. #Radonc vibes are high here!!! @agomeziturriaga @BarbaraJereczek @PaulSargos @CZamboglou @ZilliThomas @DrAndrewLoblaw @Nic...

x.com

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Influence of FLAIR Inclusion on Recurrence Patterns and Outcomes in Glioblastoma: Results from a Prospective Adaptive Radiotherapy Trial (UNITED) Presented by Suman Ghosh 🇨🇦 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 De-intensification of postoperative radiotherapy in HNSCC by omitting contralateral elective neck irradiation– long term outcomes of the DIREKHT trial Presented by Charlotte Frei 🇩🇪 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Paradigm shift from bilateral elective nodal irradiation to SPECT/CT-based SNP to guide unilateral irradiation in HNSCC: multicenter prospective study Presented by Abrahim Al-Mamgani🇳🇱

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Final results of a nationwide multicenter randomized trial (GOLD) on hypofractionated chemoradiation for glioblastoma: survival and HRQoL Presented by Anouk de Jong 🇳🇱 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Patient-informed and data-driven cumulative toxicity score as an endpoint for clinical studies: Validation in a Phase III randomized trial (PARCER) Presented by Marta Pelizzola 🇩🇰 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Five-year follow-up outcomes from JCOG1208: A single-arm confirmatory trial of IMRT alone for early-stage oropharyngeal cancer Presenter Satoaki Nakamura 🇯🇵

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Five-Year Follow-Up of the SABR 5 Trial: Primary Toxicity Analysis of Stereotactic Ablative Radiotherapy for Up to Five Oligometastases Presenter Robert Olson 🇨🇦

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Updated clinical outcomes from the RADIOSA randomized phase II trial Presented by Giulia Marvaso 🇮🇹 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Eliminating surgery for breast cancers with an exceptional response to ablative radiotherapy: phase 2 trial primary endpoints Presented by Simona F. Shaitelman 🇺🇸 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Long term results of radiation therapy de-escalation in cT1-2N1 breast cancer after primary systemic treatment (RAPCHEM, BOOG 2010-03; NCT01279304) Presented by Fleur Mauritz 🇳🇱 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 YO-HAI5 trial: 5- vs 15-fraction whole-breast irradiation with optional integrated boost: randomized phase III trial Presented by Renée De Noyette 🇧🇪 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Post-hoc analysis of metastasis-free survival (MFS) and Eugonadal MFS in the RADIOSA phase II randomized trial Presented by Giulia Marvaso 🇮🇹 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Optimizing oligometastatic disease management with circulating tumor DNA: a correlative analysis from the phase II randomized EXTEND trial Presented by Alexander Sherry 🇺🇸 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Early Toxicity of elective nodal RT for Oligorecurrent Pelvic/Paraaortic nodes in Prostate Cancer: a randomised phase 3 trial OLIGOPELVIS-2/GETUG P12 Presenter Stéphane SUPIOT🇫🇷 #ProstateCancer

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Is a boost to the tumour bed still indicated after breast-conserving surgery and whole-breast radiotherapy in the era of modern systemic therapy? Presented by Femke Froklage 🇳🇱 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Patterns of locoregional and distant recurrence and dosimetric analysis in the HypoG-01 phase III trial Presented by Louis Munschi 🇫🇷 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 OLIGOPELVIS 2-GETUG P12 elective nodal radiotherapy for oligorecurrent pelvic/para-aortic nodes in prostate cancer: early toxicity of a randomized phase 3 trial Presented by Hugo CORDA / Stéphane SUPIOT 🇫🇷 ☢️ #ProstateCancer @estroradiotherapy.bsky.social

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Impact of AI-Avatar Based Digital Patient Engagement on Treatment Understanding, Empowerment and Stress in a US Community Radiation Oncology Practice Presented by Adam Raben 🇺🇸 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Status and practice of proton therapy for pregnant patients in Europe Presented by Maite Romero-Expósito 🇸🇪 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Final Results of the TROG 15.03 FASTRACK II Clinical Trial: Stereotactic Ablative Body Radiotherapy (SABR) for Primary Kidney Cancer by Shankar Siva 🇦🇺 #KidneyCancer

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Clinical and treatment characteristics associated with local control following SBRT: interim analysis of ESTRO EORTC E2-RADIatE OligoCare cohort Presented by Umberto Ricardi 🇮🇹 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Dose escalation with intraoperative radiotherapy in newly-diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised phase 3 trial Presented by Frank A. Giordano 🇩🇪 #RadOnc ☢️

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Internal Mammary and Medial Supraclavicular irradiation in stage I-III breast cancer: 20 years results of the randomised EORTC trial 22922/10925, including in pN0 patients Presenters Philip Poortmans 🇧🇪 & Orit Kaidar 🇮🇱 @estroradiotherapy.bsky.social

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 When less is not enough: first results from the phase III randomized DBCG RT Natural trial Presenter Birgitte Vrou Offersen 🇩🇰 #RadOnc @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 10-year Follow-Up of the DBCG HYPO Trial: Breast Induration, Recurrence and Survival After Hypofractionated Whole Breast Irradiation Presented by Hanna Forsberg 🇩🇰 #RadOnc ☢️ #BreastCancer @estroradiotherapy.bsky.social

Day TWO of #ESTRO26 Coverage by OncoAlert 🚨 Electron and brachytherapy boost after breast-conserving surgery and whole breast irradiation: 30-year results of the randomized Budapest Boost Trial Presented by Csaba Polgar 🇭🇺 #RadOnc ☢️ @estroradiotherapy.bsky.social

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Conventional vs Pelvic Ultra-Hypofractionated IMRT with HDR Brachytherapy in Prostate Cancer: Early Outcomes from PCS-XI Complete Cohort(NCT05820633) Presented by François Fabi 🇨🇦 #RadOnc ☢️ #ProstateCancer @estroradiotherapy.bsky.social

Day THREE of #ESTRO26 Coverage by OncoAlert 🚨 Fifteen-year outcomes of the randomised APBI-IMRT Florence phase III trial of partial versus whole-breast irradiation in early #BreastCancer Presenter: Carlotta Becherini 🇮🇹